PRINCETON, N.J. and PARIS - January 10, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2013.

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 Full Year Sales 2012</td>
<td>24 January 2013</td>
</tr>
<tr>
<td>Full-Year Results 2012 **</td>
<td>28 March 2013</td>
</tr>
<tr>
<td>Q1 Sales 2013</td>
<td>25 April 2013</td>
</tr>
<tr>
<td>Q2 Sales 2013</td>
<td>25 July 2013</td>
</tr>
<tr>
<td>Half-Year Results 2013</td>
<td>29 August 2013</td>
</tr>
<tr>
<td>Q3 Sales 2013</td>
<td>24 October 2013</td>
</tr>
</tbody>
</table>

Financial year ended 31 December

* Subject to modification
** Press release distributed before the financial markets opening

About STENTYS:
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low 30-day mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

Contacts

**STENTYS**
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

**Europe: NewCap.**
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

**US: MacDougall Biomedical Communications**
Kari Watson, Tel.: +1 781 235 3060
Christine Labaree, Tel.: +1 650 339 7533
stentys@macbiocom.com

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT